PriceTargets.com logo

Theratechnologies - TH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$1.83 As of 12/3/2024 12:06 PM ET
▲ +0.01 (0.55%)

This chart shows the closing price for TH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Theratechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TH

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$1.83.

This chart shows the closing price for TH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Theratechnologies. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
9/27/2023National BanksharesLower TargetSector PerformC$7.00 ➝ C$5.50
8/1/2023National BanksharesBoost TargetSector PerformC$1.75 ➝ C$7.00
7/13/2023National BanksharesLower TargetC$2.25 ➝ C$1.75
4/13/2023National BanksharesLower TargetSector PerformC$3.25 ➝ C$2.25
1/5/2023Leede Jones GabUpgradeHold ➝ Speculative Buy
11/17/2022Cantor FitzgeraldReiterated RatingOverweight
7/15/2022National BanksharesLower TargetSector PerformC$3.75 ➝ C$3.25
10/14/2021National BanksharesReiterated RatingHoldC$3.75
2/26/2021Leede Jones GabDowngradeSpeculative Buy ➝ Hold
1/20/2021National Bank FinancialReiterated RatingSector PerformC$3.75
7/15/2020National Bank FinancialReiterated RatingSector Perform Market Weight
4/15/2020National Bank FinancialLower TargetSector PerformC$4.50 ➝ C$4.00
4/7/2020National Bank FinancialLower TargetSector PerformC$5.75 ➝ C$4.50
2/26/2020Echelon Wealth PartnersReiterated RatingBuy
2/3/2020National Bank FinancialLower TargetSector PerformC$6.00 ➝ C$5.75
12/20/2019National Bank FinancialLower TargetSector PerformC$7.00 ➝ C$6.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Theratechnologies logo
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: C$1.83
Low: C$1.82
High: C$1.85

50 Day Range

MA: C$1.72
Low: C$1.60
High: C$1.88

52 Week Range

Now: C$1.83
Low: C$1.59
High: C$3.43

Volume

20,816 shs

Average Volume

29,836 shs

Market Capitalization

C$84.14 million

P/E Ratio

N/A

Dividend Yield

3.76%

Beta

1.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Theratechnologies?

The following equities research analysts have issued research reports on Theratechnologies in the last year: Cantor Fitzgerald.
View the latest analyst ratings for TH.

What is the current price target for Theratechnologies?

0 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Theratechnologies in the next year.
View the latest price targets for TH.

What is the current consensus analyst rating for Theratechnologies?

Theratechnologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TH will outperform the market and that investors should add to their positions of Theratechnologies.
View the latest ratings for TH.

What other companies compete with Theratechnologies?

Other companies that are similar to Theratechnologies include CENTRIC HEALTH, Maple Gold Mines, Mount Logan Capital, Jaxon Mining and Pacific Paradym Energy. Learn More about companies similar to Theratechnologies.

How do I contact Theratechnologies' investor relations team?

Theratechnologies' physical mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company's listed phone number is +1-514-3367800. The official website for Theratechnologies is www.theratech.com. Learn More about contacing Theratechnologies investor relations.